ROTE WILLIAM E. 4

4 · Travere Therapeutics, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Travere (TVTX) Chief Research Officer William Rote Sells 12,446 Shares

What Happened

William E. Rote, Chief Research Officer of Travere Therapeutics (TVTX), sold 12,446 shares in an open-market transaction on Feb 3, 2026 for $32.87 per share, totaling $409,100. On Jan 31, 2026 he was also granted 20,090 restricted stock units (RSUs) and a separate derivative award of 53,570 units (both reported at $0.00 acquisition price).

Key Details

Sale: 12,446 shares on 2026-02-03 at $32.87 — proceeds $409,100. (Footnote F2: sale made under a written 10b5-1 plan and includes shares sold to cover tax withholding from RSU vesting.)
Grants (reported 2026-01-31): 20,090 RSUs (each RSU represents a contingent right to one share; Footnote F1) and a derivative award of 53,570 units (Footnote F3 describes vesting: 25% after one year, then monthly over 36 months).
Shares owned after the transactions are not specified in the provided excerpt of the Form 4.
Filing: Form 4 was filed on 2026-02-03 reporting the above transactions.

Context

The sale appears routine: footnote indicates it was executed under a pre-established Rule 10b5-1 plan and was used to satisfy tax withholding related to RSU vesting. The grants are awards (acquisitions) that vest over time; the derivative award follows a standard vesting schedule rather than an immediate market sale. These disclosures are factual record of insider activity and do not by themselves indicate management sentiment.

Form 4

Period: 2026-01-31

Chief Research Officer

Transactions

Award
Common Stock
[F1]
2026-01-31+20,090→ 121,533 total
Sale
Common Stock
[F2]
2026-02-03$32.87/sh−12,446$409,100→ 109,087 total
Award
Employee stock option (right to buy)
[F3]
2026-01-31+53,570→ 53,570 total
Exercise: $33.09Exp: 2036-01-31→ Common Stock (53,570 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
[F2]This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
[F3]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Signature

/s/ Elizabeth E. Reed, Attorney-in-Fact|2026-02-03

1 file